** Shares of drugmaker Bristol Myers Squibb BMY.N fall 1.6% to $50.50 in extended trading
** Co says its experimental heart disease drug, mavacamten, did not meet the main goals in a late-stage study
** The drug was being tested to treat adult patients with with the so-called non-obstructive form of hypertrophic cardiomyopathy (nHCM), an inherited condition characterized by thickening of heart muscles
** The drug, branded as Camzyos, did not improve symptoms or exercise more easily in patients with nHCM
** The drug is already approved in the U.S. for the obstructive form of the disease
** As of last close, stock down 9.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。